Adipocytokine Dysregulation, Obesity and the Metabolic Syndrome

The Metabolic Syndrome: Second Edition

Volumn , Issue , 2011, Pages 229-244

  Smith, Ulf ^a   Yang, Xiaolin ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Adipocytokines; Adiponectin; IL 6; Inflammation; Insulin resistance; Leptin; Obesity; Resistin; TNF ; Type 2 diabetes

Indexed keywords

EID: 84887530928     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444347319.ch14     Document Type: Chapter

References (126)

1. Ahima, R. S. & Osei, S. Y. (2004) Leptin signaling. Physiol Behav, 81, 223-41.
2. Ahima, R. S., Prabakaran, D., Mantzoros, C., et al. (1996) Role of leptin in the neuroendocrine response to fasting. Nature, 382, 250-2.
3. Anderson, P. D., Mehta, N. N., Wolfe, M. L., et al. (2007) Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab, 92, 2272-9.
4. Arita, Y., Kihara, S., Ouchi, N., et al. (2002) Adipocytederived plasma protein adiponectin acts as a plateletderived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation, 105, 2893-8.
5. Bajaj, M., Suraamornkul, S., Hardies, L. J., et al. (2004) Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone- treated type II diabetic patients. Int J Obes Relat Metab Disord, 28, 783-9.
6. Banerjee, R. R. & Lazar, M. A. (2003) Resistin: molecular history and prognosis. J Mol Med, 81, 218-26.
7. Berg, A. H., Combs, T. P. & Scherer, P. E. (2002) ACRP30/ adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab, 13, 84-9.
8. Bernstein, L. E., Berry, J., Kim, S., Canavan, B. & Grinspoon, S. K. (2006) Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med, 166, 902-8.
9. Bjorbaek, C., Uotani, S., Da Silva, B. & Flier, J. S. (1997) Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem, 272, 32686-95.
10. BjurselL, M., Ahnmark, A., Bohlooly, Y. M., et al. (2007) Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes, 56, 583-93.
11. Cabre, A., Lazaro, I., Girona, J., et al. (2007) Retinolbinding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. J Intern Med, 262, 496-503.
12. Chandran, M., Phillips, S. A., Ciaraldi, T. & Henry, R. R. (2003) Adiponectin: more than just another fat cell hormone? Diabetes Care, 26, 2442-50.
13. Chen, K., Li, F., Li, J., et al. (2006) Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med, 12, 425-32.
14. Combs, T. P., Pajvani, U. B., Berg, A. H., et al. (2004) A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology, 145, 367-83.
15. Conneely, K. N., Silander, K., Scott, L. J., et al. (2004) Variation in the resistin gene is associated with obesity and insulin-related phenotypes in Finnish subjects. Diabetologia, 47, 1782-8.
16. Delaigle, A. M., Jonas, J. C., Bauche, I. B., Cornu, O. & Brichard, S. M. (2004) Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology, 145, 5589-97.
17. Diez, J. J. & Iglesias, P. (2003) The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol, 148, 293-300.
18. Dominguez, H., Storgaard, H., Rask-Madsen, C., et al. (2005) Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res, 42, 517-25.
19. Dzau, V. J. (1986) Significance of the vascular reninangiotensin pathway. Hypertension, 8, 553-9.
20. Engeli, S., Schling, P., Gorzelniak, K., et al. (2003) The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol, 35, 807-25.
21. Fain, J. N., Madan, A. K., Hiler, M. L., Cheema, P. & Bahouth, S. W. (2004) Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology, 145, 2273-82.
22. Fernandez-Real, J. M. & Ricart, W. (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev, 24, 278-301.
23. Fried, S. K., Bunkin, D. A. & Greenberg, A. S. (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab, 83, 847-50.
24. Fruhbeck, G. (2001) A heliocentric view of leptin. Proc Nutr Soc, 60, 301-18.
25. Fruhbeck, G., Gomez-Ambrosi, J., Muruzabal, F. J. & Burrell, M. A. (2001) The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab, 280, E827-47.
26. Gavi, S., Stuart, L. M., Kelly, P., et al. (2007) Retinolbinding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes. J Clin Endocrinol Metab, 92, 1886-90.
27. Gerhardt, C. C., ROMERO, I. A., Cancello, R., Camoin, L. & Strosberg, A. D. (2001) Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol, 175, 81-92.
28. Goossens, G. H., Blaak, E. E. & Van Baak, M. A. (2003) Possible involvement of the adipose tissue reninangiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev, 4, 43-55.
29. Hansotia, T., Maida, A., Flock, G., et al. (2007) Extrapancreatic incretin receptors modulate glucose homeostasis, bodyweight, and energy expenditure. J Clin Invest, 117, 143-52.
30. Hennes, M. M., O'Shaughnessy, I. M., Kelly, T. M., (1996) Insulin-resistant lipolysis in abdominally obese hypertensive individuals. Role of the renin-angiotensin system. Hypertension, 28, 120-6.
31. Hotamisligil, G. S. (2003) Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord, 27 Suppl 3, S53-5.
32. Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L. & Spiegelman, B. M. (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest, 95, 2409-15.
33. Hotamisligil, G. S., Shargill, N. S. & Spiegelman, B. M. (1993) Adipose expression of tumor necrosis factoralpha: direct role in obesity-linked insulin resistance. Science, 259, 87-91.
34. Huber, J., Kiefer, F. W., Zeyda, M., et al. (2008) CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J Clin Endocrinol Metab, 93, 3215-21.
35. Hug, C., Wang, J., Ahmad, N. S., Bogan, J. S., Tsao, T. S. & Lodish, H. F. (2004) T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA, 101, 10308-13.
36. Ingelsson, E. & Lind, L. (2009) Circulating retinol-binding protein 4 and subclinical cardiovascular disease in the elderly. Diabetes Care, 32, 733-5.
37. Ingelsson, E., Sundstrom, J., Melhus, H., et al. (2009) Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Atherosclerosis, 206, 239-44.
38. Inoue, H., Ogawa, W., Asakawa, A., et al. (2006) Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab, 3, 267-75.
39. Inouye, K. E., Shi, H., Howard, J. K., et al. (2007) Absence of CC chemokine ligand 2 does not limit obesityassociated infiltration of macrophages into adipose tissue. Diabetes, 56, 2242-50.
40. Janke, J., Engeli, S., Gorzelniak, K., Luft, F. C. & Sharma, A. M. (2002) Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes, 51, 1699-707.
41. Jellema, A., Plat, J. & Mensink, R. P. (2004) Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state. Eur J Clin Invest, 34, 766-73.
42. Jia, W., Wu, H., Bao, Y., Wang, C., Lu, J., Zhu, J. & Xiang, K. (2007) Association of serum retinol-binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin Endocrinol Metab, 92, 3224-9.
43. Kamohara, S., Burcelin, R., Halaas, J. L., Friedman, J. M. & Charron, M. J. (1997) Acute stimulation of glucose metabolism in mice by leptin treatment. Nature, 389, 374-7.
44. Kanda, H., Tateya, S., Tamori, Y., et al. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest, 116, 1494-505.
45. Kaser, S., Kaser, A., Sandhofer, A., et al. (2003) Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun, 309, 286-90.
46. Kern, P. A., Saghizadeh, M., Ong, J. M., Bosch, R. J., Deem, R. & Simsolo, R. B. (1995) The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest, 95, 2111-9.
47. Kim, H. J., Higashimori, T., Park, S. Y., et al. (2004) Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes, 53, 1060-7.
48. Kim, K. H., Lee, K., Moon, Y. S. & Sul, H. S. (2001) A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem, 276, 11252-6.
49. Kim, S. J., Nian, C. & McIntosh, C. H. (2007) Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem, 282, 34139-47.
50. Kirk, E. A., Sagawa, Z. K., McDonald, T. O., O'Brien, K. D. & Heinecke, J. W. (2008) Monocyte chemoattractant protein deficiency fails to restrain macrophage infiltration into adipose tissue [corrected]. Diabetes, 57, 1254-61.
51. Klover, P. J., Zimmers, T. A., Koniaris, L. G. & Mooney, R. A. (2003) Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes, 52, 2784-9.
52. Kondo, H., Shimomura, I., Matsukawa, Y., et al. (2002) Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes, 51, 2325-8.
53. Kubota, N., Terauchi, Y., Yamauchi, T., et al. (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem, 277, 25863-6.
54. Lee, J. H., Chan, J. L., Yiannakouris, N., et al. (2003) Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab, 88, 4848-56.
55. Lee, Y., Wang, M. Y., Kakuma, T., et al. (2001) Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem, 276, 5629-35.
56. Lehrke, M., Reilly, M. P., Millington, S. C., et al. (2004) An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med, 1, e45.
57. Li, L., Wu, L., Wang, C., Liu, L. & Zhao, Y. (2007) Adiponectin modulates carnitine palmitoyltransferase-1 through AMPK signaling cascade in rat cardiomyocytes. Regul Pept, 139, 72-9.
58. Liu, Y., Michael, M. D., Kash, S., et al. (2007) Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes. Endocrinology, 148, 683-92.
59. Lo, J., Bernstein, L. E., Canavan, B., et al. (2007) Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab, 293, E102-9.
60. Ma, L. J., Mao, S. L., Taylor, K. L., et al. (2004) Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes, 53, 336-46.
61. Maeda, K., Okubo, K., Shimomura, I., et al. (1997) Analysis of an expression profile of genes in the human adipose tissue. Gene, 190, 227-35.
62. Maffei, M., Halaas, J., Ravussin, E., et al. (1995) Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med, 1, 1155-61.
63. Mallat, Z., Simon, T., Benessiano, J., et al. (2009) Retinolbinding protein 4 and prediction of incident coronary events in healthy men and women. J Clin Endocrinol Metab, 94, 255-60.
64. Martin, S. S., Qasim, A. & Reilly, M. P. (2008) Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol, 52, 1201-10.
65. Massiera, F., Bloch-Faure, M., Ceiler, D., et al. (2001) Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. Faseb J, 15, 2727-9.
66. Masuzaki, H., Yamamoto, H., Kenyon, C. J., et al. (2003) Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest, 112, 83-90.
67. Mavri, A., Alessi, M. C. & Juhan-Vague, I. (2004) Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases. J Intern Med, 255, 448-56.
68. Menzaghi, C., Coco, A., Salvemini, L., et al. (2006) Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians. J Clin Endocrinol Metab, 91, 2792-5.
69. Mertens, I. & Van Gaal, L. F. (2002) Obesity, haemostasis and the fibrinolytic system. Obes Rev, 3, 85-101.
70. Minokoshi, Y., Kim, Y. B., Peroni, O. D., et al. (2002) Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature, 415, 339-43.
71. Mohamed-Ali, V., Goodrick, S., Rawesh, A., et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab, 82, 4196-200.
72. Mohlig, M., Weickert, M. O., Ghadamgahi, E., et al. (2008) Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome. Eur J Endocrinol, 158, 517-23.
73. Morash, B. A., Ur, E., Wiesner, G., Roy, J. & Wilkinson, M. (2004) Pituitary resistin gene expression: effects of age, gender and obesity. Neuroendocrinology, 79, 149-56.
74. Muse, E. D., Lam, T. K., Scherer, P. E. & Rossetti, L. (2007) Hypothalamic resistin induces hepatic insulin resistance. J Clin Invest, 117, 1670-8.
75. Ochi, M., Osawa, H., Hirota, Y., et al. (2007) Frequency of the G/G genotype of resistin single nucleotide polymorphism at -420 appears to be increased in younger-onset type 2 diabetes. Diabetes, 56, 2834-8.
76. Ouchi, N., Kihara, S., Arita, Y., et al. (1999) Novel modulator for endothelial adhesion molecules: adipocytederived plasma protein adiponectin. Circulation, 100, 2473-6.
77. Ouchi, N., Kihara, S., Arita, Y., et al. (2001) Adipocytederived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation, 103, 1057-63.
78. Park, S. E., Kim, D. H., Lee, J. H.,et al. (2009) Retinolbinding protein-4 is associated with endothelial dysfunction in adults with newly diagnosed type 2 diabetes mellitus. Atherosclerosis, 204, 23-5.
79. Patel, S. D., Rajala, M. W., Rossetti, L., Scherer, P. E. & Shapiro, L. (2004) Disulfide-dependent multimeric assembly of resistin family hormones. Science, 304, 1154-8.
80. Pineiro, R., Iglesias, M. J., Gallego, R., et al. (2005) Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett, 579, 5163-9.
81. Preitner, F., Mody, N., Graham, T. E., Peroni, O. D. & Kahn, B. (2009) Long-term fenretinide treatment prevents high fat diet-induced obesity, insulin resistance and hepatic steatosis. Am J Physiol Endocrinol Metab, 297, E 1420-29.
82. Prodi, E. & Obici, S. (2006) Minireview: the brain as a molecular target for diabetic therapy. Endocrinology, 147, 2664-9.
83. Qi, Q., Yu, Z., Ye, X., et al. (2007) Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab, 92, 4827-34.
84. Rajala, M. W., Obici, S., Scherer, P. E. & Rossetti, L. (2003) Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest, 111, 225-30.
85. Rajala, M. W., Qi, Y., Patel, H. R., et al. (2004) Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes, 53, 1671-9.
86. Reilly, M. P., Lehrke, M., Wolfe, M. L., et al. (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation, 111, 932-9.
87. Rossetti, L., Massillon, D., Barzilai, N., et al. (1997) Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action. J Biol Chem, 272, 27758-63.
88. Ruan, H., Miles, P. D., Ladd, C. M., et al. (2002) Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes, 51, 3176-88.
89. Saiki, A., Ohira, M., Endo, K., et al. (2009) Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus. Metabolism, 58, 708-13.
90. Savage, D. B., Sewter, C. P., Klenk, E. S., et al. (2001) Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes, 50, 2199-202.
91. Schafer, K., Fujisawa, K., Konstantinides, S. & Loskutoff, D. J. (2001) Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. Faseb J, 15, 1840-2.
92. Senn, J. J., Klover, P. J., Nowak, I. A. & Mooney, R. A. (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes, 51, 3391-9.
93. Senn, J. J., Klover, P. J., Nowak, I. A., et al. (2003) Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem, 278, 13740-6.
94. Singhal, N. S., Lazar, M. A. & Ahima, R. S. (2007) Central resistin induces hepatic insulin resistance via neuropeptide Y. J Neurosci, 27, 12924-32.
95. Siwik, D. A., Chang, D. L. & Colucci, W. S. (2000) Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res, 86, 1259-65.
96. Stefan, N., Hennige, A. M., Staiger, H., et al. (2007) High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care, 30, 1173-8.
97. Stenlof, K., Wernstedt, I., Fjallman, T., et al. (2003) Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. J Clin Endocrinol Metab, 88, 4379-83.
98. Steppan, C. M., Bailey, S. T., Bhat, S., et al. (2001) The hormone resistin links obesity to diabetes. Nature, 409, 307-12.
99. Takahashi, K., Mizuarai, S., Araki, H., et al. (2003) Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem, 278, 46654-60.
100. Takahashi, M., Arita, Y., Yamagata, K., et al. (2000) Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord, 24, 861-8.
101. Takebayashi, K., Suetsugu, M., Wakabayashi, S., ASO, Y. & Inukai, T. (2007) Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab, 92, 2712-9.
102. Tartaglia, L. A. (1997) The leptin receptor. J Biol Chem, 272, 6093-6.
103. Tilg, H. & Moschen, A. R. (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol, 6, 772-83.
104. Trayhurn, P. & Wood, I. S. (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr, 92, 347-55.
105. Uysal, K. T., Wiesbrock, S. M., Marino, M. W. & Hotamisligil, G. S. (1997) Protection from obesityinduced insulin resistance in mice lacking TNF-alpha function. Nature, 389, 610-4.
106. Von Eynatten, M., Lepper, P. M., Liu, D., et al. (2007) Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia, 50, 1930-7.
107. Wajchenberg, B. L. (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev, 21, 697-738.
108. Waki, H., Yamauchi, T., Kamon, J., et al. (2005) Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology, 146, 790-6.
109. Wallenius, V., Wallenius, K., Ahren, B., et al. (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med, 8, 75-9.
110. Weisberg, S. P., Hunter, D., Huber, R., et al. (2006) CCR2 modulates inflammatory and metabolic effects of highfat feeding. J Clin Invest, 116, 115-24.
111. Weisberg, S. P., McCann, D., Desai, M., et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest, 112, 1796-808.
112. Wellen, K. E. & Hotamisligil, G. S. (2003) Obesity-induced inflammatory changes in adipose tissue. J Clin Invest, 112, 1785-8.
113. Wolf, A. M., Wolf, D., Avila, M. A., et al. (2006) Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. J Hepatol, 44, 537-43.
114. Wolf, A. M., Wolf, D., Rumpold, H., Enrich, B. & Tilg, H. (2004) Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun, 323, 630-5.
115. Xu, H., Barnes, G. T., Yang, Q., et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest, 112, 1821-30.
116. Xu, J. Y., Sham, P. C., Xu, A., et al. (2007) Resistin gene polymorphisms and progression of glycaemia in southern Chinese: a 5-year prospective study. Clin Endocrinol (Oxf), 66, 211-7.
117. Yamaguchi, N., Argueta, J. G., Masuhiro, Y., et al. (2005) Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett, 579, 6821-6.
118. Yamauchi, T., Kamon, J., Ito, Y., et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 423, 762-9.
119. Yamauchi, T., Nio, Y., Maki, T., et al. (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med, 13, 332-9.
120. Yanagisawa, M., Kurihara, H., Kimura, S., et al. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332, 411-5.
121. Yang, Q., Graham, T. E., Mody, N., et al. (2005) Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature, 436, 356-62.
122. Yang, X. & Smith, U. (2007) Adipose tissue distribution and risk of metabolic disease: does thiazolidinedioneinduced adipose tissue redistribution provide a clue to the answer? Diabetologia, 50, 1127-39.
123. Yao-Borengasser, A., Varma, V., Bodles, A. M., et al. (2007) Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab, 92, 2590-7.
124. Yusuf, S. (2002) From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol, 89, 18A-25A; discussion 25A-26A.
125. Zhang, Y., Proenca, R., Maffei, M., et al. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature, 372, 425-32.
126. Zirlik, A., Ernst, S., Leugers, A., et al. (2009) Inhibition by fibrates of plasminogen activator inhibitor type-1 expression in human adipocytes and preadipocytes. Thromb Haemost, 101, 1060-9.